INTRODUCTION {#s1}
============

The prevalence of type 2 diabetes mellitus is expected to reach 5.4%, affecting approximately 300 million by 2025 globally \[[@R1]\]. Diabetes, especially if glycemic control is poor, causes damage to multiple organ systems, leading to significant morbidity and mortality. For example, it can result in cardiac hypertrophy, cardiomyopathy and heart failure \[[@R2], [@R3]\]. Histologically, this is reflected by the increased amount of fibrotic tissue within the myocardium \[[@R4]\]. In addition to mechanical dysfunction, this can lead to impaired conduction of action potentials \[[@R5]\], increasing the likelihood of re-entrant arrhythmias and sudden cardiac death \[[@R6]\].

Recent research efforts have focused on elucidating the molecular mechanisms by which increased oxidative stress is generated in diabetes, and how this leads to vascular and cardiac dysfunction \[[@R7]--[@R9]\]. Recently, our group demonstrated that higher levels of oxidative stress were associated with increased atrial fibrosis in an alloxan-induced diabetic rabbit model \[[@R10]--[@R13]\]. In the ventricles, reactive oxidant species (ROS) can also promote cardiac hypertrophy, fibrosis, contractile dysfunction and eventually pump failure \[[@R14]\]. The primary sources of ROS include the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, mitochondria, xanthine oxidases, and uncoupled NO synthases (NOS) \[[@R14]\], while NADPH oxidase (NOX) activates redox signaling, in turn causing tissue injury \[[@R15], [@R16]\].

Apocynin is an effective inhibitor of NADPH oxidase \[[@R17]\] by preventing p47phox assembly to the enzyme core \[[@R18]\]. In this study, we tested the hypothesis that this agent may protect against ventricular hypertrophy and fibrosis in an alloxan-induced diabetes model in rabbits. This was achieved by experiments conducted at different levels of complexity, from hemodynamic and mechanical functions at the whole organ level, to determination of protein levels and activity of pro- and anti-oxidant enzymes at the tissue level.

RESULTS {#s2}
=======

Body weight, blood, hemodynamic and echocardiographic parameters {#s2_1}
----------------------------------------------------------------

Our initial experiments confirmed that alloxan successfully induced diabetes in the rabbits after 6 weeks, leading to lower body weight, increased glucose levels and decreased insulin levels compared to control (Table [1](#T1){ref-type="table"}) (*P* \< 0.05). Apocynin treatment did not alter these parameters. There were no differences in blood urea nitrogen, creatinine, total cholesterol, triglyceride or low density lipoprotein levels between the three groups. Whilst high density lipoprotein was not significantly different between the control and diabetic groups, we observed a reduction in its levels with the apocynin group.

###### Body weight and blood parameters

                                      Control group (*n* = 10)   Diabetes group (*n* = 10)   Apocynin group (*n* = 10)
  ----------------------------------- -------------------------- --------------------------- ---------------------------
  Weight, kg                          2.71 ± 0.28                2.32 ± 0.36\*               2.53 ± 0.49
  Glucose, mmol/L                     5.43 ± 0.75                17.72 ± 6.19\*              19.61 ± 5.21
  Insulin, uIU/mL                     16.04 ± 1.40               7.56 ± 1.34\*               7.01 ± 1.21
  Blood Urea Nitrogen (mmol/L)        6.54 ± 1.26                7.14 ± 1.36                 7.28 ± 1.01
  Creatinine (umol/L)                 91.60 ± 12.18              99.74 ± 10.80               104.50 ± 12.05
  Total cholesterol (mmol/L)          1.63 ± 0.13                1.84 ± 0.28                 1.50 ± 0.53
  Triglyceride (mmol/L)               1.13 ± 0.34                1.39 ± 0.47                 1.26 ± 0.52
  High Density Lipoprotein (mmol/L)   0.94 ± 0.28                0.90 ± 0.30                 0.58 ± 0.20\#
  Low Density Lipoprotein (mmol/L)    0.59 ± 0.10                0.70 ± 0.29                 0.61 ± 0.14

Values are mean ± SD; \*Compared with control (*P* \< 0.05). \#Compared with the diabetic group (*P* \< 0.05).

No significant differences in systolic and diastolic blood pressures, or in left ventricular end-point pressure were observed between controls, diabetes group alone and diabetes group with apocynin treatment (Table [2](#T2){ref-type="table"}). Representative echocardiographic images in the parasternal long axis view are shown in Figure [1](#F1){ref-type="fig"}. Left atrial antero-posterior diameter, interventricular septal thickness and left ventricular posterior wall thickness were significantly increased in the diabetes group (*P* \< 0.05). Increases in the latter two parameters were attenuated by apocynin treatment (*P* \< 0.05). No differences in left ventricular end-diastolic or end-systolic diameters or in left ventricular ejection fraction were observed (*P \>* 0.05).

###### Hemodynamic and echocardiographic parameters

                                                  Control group(*n* = 10)   Diabetes group(*n* = 10)   Apocynin group(*n* = 10)
  ----------------------------------------------- ------------------------- -------------------------- --------------------------
  Systolic blood pressure, mmHg                   112.5 ± 7.53              113.7 ± 6.90               115.4 ± 8.81
  Diastolic blood pressure, mmHg                  85.2 ± 5.49               86.6 ± 5.34                90.3 ± 8.21
  Left ventricular end-diastolic pressure, mmHg   −7.4 ± 2.32               −6.0 ± 5.31                −8.6 ± 2.80
  Left atrial antero-posterior diameter, mm       6.88 ± 0.42               8.53 ± 0.81\*              7.77 ± 1.25
  Interventricular septal thickness, mm           1.71 ± 0.09               2.13 ± 0.25\*              1.91 ± 0.14\#
  Left ventricular posterior wall thickness, mm   1.67 ± 0.07               2.10 ± 0.25\*              1.89 ± 0.13\#
  Left ventricular end-diastolic diameter, mm     12.4 ± 0.64               13.42 ± 1.44               13.60 ± 1.43
  Left ventricular end-systolic diameter, mm      7.12 ± 0.57               7.90 ± 1.39                7.72 ± 0.50
  Left ventricular ejection fraction, %           72.14 ± 6.0               73.55 ± 9.41               74.88 ± 6.70

Values are mean ± SD; \*Compared with control (*P* \< 0.05). \#Compared with the diabetic group (*P* \< 0.05).

![Representative parasternal long-axis echocardiographic views in the control (**A**), diabetic group (**B**) and apocynin treatment group (**C**). Abbreviations: LA = left atrium; LV = left ventricle; AO = aorta.](oncotarget-08-38482-g001){#F1}

Left ventricular hypertrophy and interstitial fibrosis {#s2_2}
------------------------------------------------------

After echocardiographic and hemodynamic assessments, the hearts were weighed as a whole and for the left ventricle only. Whole heart weight and left ventricular weight ratios were significantly increased in the diabetic group compared with controls but not further altered by apocynin (*P* \< 0.05) (Table [3](#T3){ref-type="table"}). Mean cross-sectional area of cardiomyocytes from the left ventricle was higher (Figure [2](#F2){ref-type="fig"}) and greater amount of interstitial fibrosis, as measured by the left ventricular interstitial collagen volume fraction (Figure [3](#F3){ref-type="fig"}), were observed in the diabetes group compared to control (*P* \< 0.05). These changes were prevented by apocynin treatment (*P* \< 0.05).

###### Heart weights, oxidative stress parameters and NADPH oxidase activity

                                                     Control group(*n*=10)   Diabetes group(*n*=10)   Apocynin group(*n*=10)
  -------------------------------------------------- ----------------------- ------------------------ ------------------------
  Heart weight ratio, 1/1,000                        2.24 ± 0.11             2.41 ± 0.16\*            2.32 ± 0.21
  LV weight ratio, 1/1,000                           1.53 ± 0.07             1.75 ± 0.14\*            1.66 ± 0.14
  Nitric oxide, umol/L                               94.99 ± 14.24           137.08 ± 25.43\*         109.02 ± 22.17\#
  Superoxide dismutase,U/ml                          458.22 ± 63.46          484.80 ± 67.29           565.10 ± 70.76\#
  Myeloperoxidase, U/L                               51.23 ± 9.40            60.18 ± 8.56\*           53.20 ± 6.91
  Malonaldehyde, nmol/ml                             9.70 ± 2.27             14.47 ± 2.74\*           10.88 ± 1.70\#
  NADPH oxidase activity,umol NADPH/min/mg protein   22.69 ± 6.06            49.79 ± 8.78\*           33.18 ± 8.30\#

Values are mean ± SD; \*Compared with control (*P* \< 0.05). \#Compared with the diabetic group (*P* \< 0.05). NADPH = nicotinamide adenine dinucleotide phosphate.

![Left ventricular cardiomyocytes (×400) evaluated with H&E staining in the control (**A**), diabetic group (**B**) and apocynin treatment group (**C**). (**D**): Demonstrates cardiomyocyte mean cross sectional area in each groups. \* and \# indicate significant difference when apocynin treatment group was compared with control group and the diabetes group, respectively (*P* \< 0.05).](oncotarget-08-38482-g002){#F2}

![Interstitial fibrosis (×400) in the control (**A**), diabetic group (**B**) and apocynin treatment group (**C**). (**D**): Left ventricular interstitial collagen volume fraction (LVCVF), expressed as a percentage in each group. \* and \# indicate significant difference when apocynin treatment group was compared with control group and the diabetes group, respectively (*P* \< 0.05).](oncotarget-08-38482-g003){#F3}

Oxidative stress parameters and western blotting for protein expression levels {#s2_3}
------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} summarizes the oxidative stress parameters. Compared with the control group, serum nitric oxide, myeloperoxidase and malondialdehyde levels, as well as NADPH oxidase activity were significantly increased in the diabetic group (*P* \< 0.05). Apocynin significantly decreased serum nitric oxide and malondialdehyde levels and NADPH oxidase activity back to control values (*P* \< 0.05) and increased serum SOD levels (*P* \< 0.05).

Figure [4](#F4){ref-type="fig"} shows representative Western blots for the protein expression involved in pro-inflammatory and fibrotic signaling pathways. Expression levels of transforming growth factor-beta (TGF-β, A), metalloproteinase-9 (MMP-9, B), nuclear factor kappa B (NF-κB, C), Ras-related C3 botulinum toxin substrate 1 (rac1, F), p38 (G) and phosphorylated p38 (H) were significantly in the diabetic group compared to controls. All of these changes were prevented by apocynin treatment. By contrast, expression of gp91phox (D) and p22phox (E) were not significantly different between the three groups (*P* \< 0.05).

![Western blotting results for transforming growth factor-beta (TGF- β, **A**), metalloproteinase-9 (MMP-9, **B**), nuclear factor kappa B (NF-κB, **C**), gp91phox (**D**), p22phox (**E**), Ras-related C3 botulinum toxin substrate 1 (rac1, **F**), p38 (**G**), phosphorylated p38 (**H**) normalized to β-actin. Values are expressed as mean ± SD \* and \# indicate significant difference when apocynin treatment group was compared with control group and the diabetes group, respectively (*P* \< 0.05).](oncotarget-08-38482-g004){#F4}

DISCUSSION {#s3}
==========

The major findings of the present study are as follows: Diabetes (1) induced left ventricular hypertrophy without altering mechanical function as evidenced by echocardiography, (2) increased mean cross-sectional area of cardiomyocytes and increased interstitial fibrosis, (3) increased serum nitric oxide, myeloperoxidase and malondialdehyde levels, (4) increased NADPH oxidase (NOX) activity and (5) increased protein expression levels of several pro-inflammatory and pro-fibrotic signaling components, including transforming growth factor-beta (TGF-β), metalloproteinase-9 (MMP-9), nuclear factor kappa B (NF-κB), Ras-related C3 botulinum toxin substrate 1 (rac1), p38 and phosphorylated p38. (6) The NOX inhibitor, apocynin, prevented most of these pathological changes, and additionally increased superoxide dismutase levels.

Higher levels of oxidative stress are known to promote inflammation, fibrosis, and apoptosis \[[@R19]\]. Cellular hypertrophy and fibrosis, features commonly observed in diabetic cardiomyopathy \[[@R4]\], are promoted by increased reactive oxygen species (ROS) production \[[@R20]--[@R23]\]. In diabetic cardiomyopathy, interstitial fibrosis occurs primarily as a result of increased type III collagen deposition \[[@R22]--[@R24]\]. Hyperglycemia enhances the glycation of proteins and lipids \[[@R25]\], and activates NOX via protein kinase C (PKC) \[[@R26]\]. NOX is a major source of ROS \[[@R14]\] and plays a critical role in hyperglycemia-induced oxidative stress in the heart \[[@R27]\]. Increased NOX-dependent ROS production has been confirmed in hearts isolated from diabetic animals and cultured cardiomyocytes exposed to high glucose concentrations \[[@R28], [@R29]\]. The catalytic subunits of NOX include gp91phox and p22phox. Our Western blot experiments showed no differences in p22phox and gp91phox between control, diabetes alone or diabetes treated with apocynin. Rac1 is a cofactor for assembly of the active NOX complex \[[@R30], [@R31]\]. It has been shown that cardiomyocyte-specific Rac1 deficiency reduced ROS production and prevented cardiac fibrosis and hypertrophy in STZ-induced diabetic mice \[[@R32]\]. In our experiments, we demonstrated upregulation of Rac1 in diabetes. These findings suggest that enzyme activation rather than transcriptional control was responsible for the enhanced NOX activity \[[@R33], [@R34]\].

Increased oxidative stress can activate NF-κB, a major transcriptional regulator that can induce the expression of TGF-β, resulting in fibrosis \[[@R35]\]. The mitogen-activated protein kinase family is involved in a diverse number of regulatory processes, include response to growth signals, apoptosis, and stress \[[@R15]\]. One of these kinases is the p38 MAPK. In isolated perfused rat hearts, p38-MAPK are activated by increased oxidative stress \[[@R36]\]. In our study, the fact that expression of this kinase was also raised suggested that cardiac fibrosis and hypertrophy may be dependent on this signaling pathway.

There are many approaches that can be used to reduce oxidative stress. Oxidation processes of proteins and lipids by ROS may be so rapid, that scavenging antioxidants, such as vitamins C and E, may not able to counteract their actions. Indeed, experimental evidence suggests that upstream therapies may be more effective to prevent oxidative damage by inhibiting ROS formation \[[@R37]\], rather than acting to reduce their damage once they are formed. A potential target would be NOX, which is inhibited by the agent apocynin. Previous experiments have shown that apocynin can prevent endothelial dysfunction in diabetic rats \[[@R38]\]. It ameliorated ventricular hypertrophy and fibrosis in a rabbit myocardial infarction model of heart failure \[[@R18]\]. It also decreased tachycardia-induced TGF-β1-mediated atrial fibrosis \[[@R39]\].

In conclusion, our data demonstrate that apocynin can prevent structural remodeling in diabetes. Further studies are needed to examine whether it can similar prevent abnormal electrophysiological remodeling to reduce the incidence of ventricular arrhythmias in diabetic cardiomyopathy.

MATERIALS AND METHODS {#s4}
=====================

Study design and preparation of the rabbit DM model {#s4_1}
---------------------------------------------------

The experiments described in this study was approved by the Experimental Animal Administration Committee of Tianjin Medical University. Thirty Japanese rabbits (1.8--2.5 kg) were obtained from Beijing Medical Animals Research Institute (Beijing, China). They were randomly assigned into 3 groups (*n* = 10 for each group): control, alloxan-induced diabetic group, and diabetic group treated with oral apocynin (Sigma, Saint Louis, MO, USA) at 15mg/day/kg.

In the diabetes groups, alloxan monohydrate (Sigma, Saint Louis, MO, USA) was dissolved in sterile normal saline to achieve a concentration of 5% (W/V), and a dose of 120 mg/kg was quickly administered intravenously into the marginal ear vein. The presence of diabetes mellitus was confirmed 48 hours later by blood glucose levels showing values ≥ 14 mmol/L (one measurement) or ≥ 11 mmol/L (two measurements). Blood glucose levels were monitored weekly using the Optium Xceed glucometer (Abbott, Bedford, USA).

Echocardiography {#s4_2}
----------------

After 8 weeks, echocardiography was performed as described previously \[[@R10]\]. Briefly, 30 rabbits were anesthetized by injection of 3% pelltobarbitalum natricum (30 mg/kg) into the marginal ear vein, and were placed on the table in the left lateral position. The thoracic wall was shaved, and six cardiac cycles of parasternal long-axis and short-axis images were recorded. The following 2D measurements were obtained from the parasternal long-axis view: left atrial anteroposterior diameter, interventricular septal thickness, left ventricular posterior wall thickness, left ventricular end-systolic dimensions and left ventricular end-diastolic dimensions. The left ventricular ejection fraction (LVEF) was also determined.

Hemodynamic studies {#s4_3}
-------------------

Following echocardiographic examination, the rabbits were intravenously heparinized (1,200 IU) via the marginal ear vein. Carotid vein blood was collected for serum biochemical tests. The right carotid artery was isolated surgically. A catheter was inserted into the carotid artery to measure aortic systolic and diastolic blood pressure. Subsequently it was inserted into the left ventricle to measure the LV end-diastolic pressure.

Histological studies {#s4_4}
--------------------

Following the hemodynamic studies, the hearts were removed. The wet weights (mg) of the left ventricle and the whole heart were measured. The left ventricular tissue was placed in 4% paraformaldehyde, embedded in paraffin, and cut into 5 mm cross-sections. The specimens were stained by hematoxylin and eosin (H&E) and cardiomyocyte cross-sectional area with the investigator blinded to the group of the rabbit. Ten random fields were studied per animal whereas the cardiomyocyte cross-sectional area was evaluated from myocytes cut in the short axis with an obvious nucleus. Masson\'s trichrome staining (Nanjing Jiancheng Bioengineering Institute, China) was used to evaluate ventricular interstitial fibrosis. Microphotographs were digitized using PHOTOSHOP 7.0 (Adobe, San Jose, CA) while cardiomyocyte cross-sectional area and areas of fibrosis were analyzed using Image PRO PLUS 7.0 SCION image software (Scion co., Frederick, MD, USA). The left ventricular interstitial collagen volume fraction (LVCVF) was defined as a quantitative ratio of the area of fibrosis to the area of the reference tissue.

Serum biochemical and oxidative stress parameters, and ventricular myocardial NADPH oxidase activity {#s4_5}
----------------------------------------------------------------------------------------------------

Serum biochemical parameters included: fasting insulin levels, blood urea nitrogen, creatinine, triglyceride, total cholesterol, high density lipoprotein and low density lipoprotein. Serum antioxidant enzyme activities, including nitric oxide, malondialdehyde, myeloperoxidase and superoxide dismutase, were measured using antioxidant enzyme activity kits (Nanjing Jiancheng Bioengineering Institute, China) according to the manufacturer\'s instructions. NOX activity was assessed using a GENMED kit (Genmed Scientifics Inc., Shanghai, China) by colorimetry. Proteins was extracted from the left ventricle and NOX activity was measured according to the manufacturer\'s instructions.

Western blotting experiments {#s4_6}
----------------------------

Frozen left ventricular tissues (100 mg) were grounded and lysed with RIPA lysis buffer. The lysates were boiled for 30 minutes and centrifuged at 12,000 rpm for 6 minutes. The proteins were loaded onto SDS-polyacrylamide gels and underwent electrophoresis. The proteins were then electro-blotted onto the PVDF membranes (Millipore, USA). Subsequently, the membranes were separately incubated with rabbit polyclonal to transforming growth factor-β1 (TGF-β1) antibody (Abcam, USA, 1:5000 dilution), nuclear factor kappa B (NF-κB) P65 antibody (Abcam, USA, 1:1000 dilution), p38 antibody (Abcam, USA, 1:1000 dilution), P-p38 antibody (Abcam, USA, 1:1000 dilution), MMP-9 antibody (Abcam, USA, 1:500 dilution), p22phox antibody(1:1000 dilution), gp91phox antibody(1:500 dilution), rac1 antibody(1:1000 dilution), and were incubated with appropriate peroxidase-conjugated secondary antibodies. Reactive blots were visualized by using Western Lightning^TM^ Chemiluminescence Reagent (Millipore) and quantified using densitometry.

Statistical analysis {#s4_7}
--------------------

Statistical analysis was performed using SPSS 13.0 statistical software. All data are expressed as means ± standard deviation, Differences between groups were assessed using the Student\'s *t-test* (unpaired), and differences between three groups were analyzed by one-way ANOVA with post-hoc comparisons by the LSD test. A two-tailed *P-value* \< 0.05 was considered statistically significant.
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